Viewpoint
Apalutamide Does Not Diminish HRQoL in CRPC
By
Findings from the SPARTAN trial show that HRQoL is not diminished by adding apalutamide to androgen deprivation therapy in men with asymptomatic, nonmetastatic CRPC.
More Viewpoints
Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
By
The Leukemia & Lymphoma Society partnered with Sutro Biopharma to test the safety of the investigational CD74-targeting antibody-drug conjugate STRO-001 for 2 blood cancers.
Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
By
A matching-adjusted indirect comparison concluded that ponatinib offers better disease control compared with bosutinib in certain patients.
Latest News
Lenalidomide Induces Immunity, Produces Clinical Response in CLL
Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
Featured Content
Bleomycin-induced toxicity
Avoid pulmonary toxicity in advanced Hodgkin lymphoma patients.